Our experienced team has taken multiple companies through seed to successful exit. We have deep investment and hands on operational expertise backed by a network of Operational Partners and Advisors that you can lean on to help build your company. Takeda Digital Ventures is operated by a lean investment team, leveraging expertise from its operations and support team as well as leaning heavily on colleagues through Takeda to fulfil its mission.
Bruce Meadows, Managing Partner
Mr Meadows has been a Partner of several healthcare investment funds since 1999. First working with N M Rothschild and then GBS Ventures in Australia, his career moved to Switzerland in 2005 where he completed his MBA.
Upon completing his MBA, Bruce saw the importance in having operational experience as an investor and so joined Stryker Orthopedics, leading their European thoracolumbar spine business. Here he managed a €20 million brand, helping it grow 20% year on year and launching four products during his tenure. Through a matrix organization he had responsibility for the European group’s sales and marketing activities and influenced the manufacturing and R&D activities. Bruce spent a great deal of his time in the operating room, being as close to the healthcare professional and patient as possible, a value he takes with him in his investing career.
Next Bruce was recruited as a founding Partner of Ares Life Sciences, a €1 billion fund investing in all stages of healthcare companies. Here he was involved in several transactions including the Leveraged Buy Out of Esaote, an Italian medical imaging company developing advanced data analysis and connectivity tools. His next investment role was at MD Start, an incubation stage fund where he was involved in founding several companies including CorWave and LimFlow.
Previous to Takeda Digital Ventures, Bruce was the Senior Investment Director of MTIP, a Swiss based healthcare fund. Here Bruce led the group in its digital health strategy that ultimately led to its investment in Tyto Care Inc and Quanta Dialysis Technologies.
Bruce has been a director of many portfolio companies, leading them through IPOs and trade sales.
In his spare time, Bruce has been a part time Professor of Entrepreneurial Finance at Webster University where was able to give back to the next generation of entrepreneurs and help them be better equipped for success. Bruce has an MBA from IMD in Lausanne (Switzerland) and a First Class Honors Degree in Biotechnology from the University of Queensland (Australia).
Thomas Kluz, Investment Partner
Mr Kluz has been an investment professional at several investment funds and a healthcare entrepreneur since 2008. He began his venture capital and private equity career at Adams Street Partners in Chicago where he focused on technology and healthcare growth-equity.
After his time at Adams Street Partners, Thomas decided to gain some operational experience by joining a burgeoning medtech startup under the auspices of Northwestern Medicine focused on developing a point-of-care cancer diagnostic. He led business development and strategic partnerships for the company, which resulted in $5M in capital financing, a large-scale clinical trial, and an acquisition by a large multi-national. In addition to his business development role, Thomas spent a great deal of his time running the day-to-day operations of the organization, including clinical trial management, human resources, strategic finance and technology development, all lessons he reflects on while working with entrepreneurs as an investor.
Next Thomas was recruited to join Providence Ventures, the $300M venture capital arm of Providence St. Joseph Health, one of the largest integrated delivery networks in the United States where he focused on investing in digital health, medical device and diagnostic companies. Here he was involved in several transactions including the growth-equity investment in Collective Medical Technologies, a Kleiner Perkins-backed focused HIE solution providing value-added applications to both payors and providers. He was also involved with investments in Lyra Health, Xealth and Wildflower Health.
Prior to Takeda Digital Ventures, Thomas was a General Partner of dRx Capital, a joint venture capital fund between Qualcomm Ventures and Novartis. Here Thomas led Qualcomm’s digital health strategy where he served as a valued strategic advisor and coach to portfolio companies as well as operating executives throughout Qualcomm and Novartis business units. He led/supported the firm’s investments in Aktana, AliveCor, Cala Health, Science 37 and Tyto Care. Thomas was also a board member of Doctor on Demand, Common Sensing and Welltok.
When he is not working, Thomas enjoys traveling, rowing, skiing and other endurance sports. Thomas has a Master of Science and a Bachelor of Science in Biomedical Engineering from Northwestern University where he is a published author in the Journal of Surgical Oncology.
Dr. Claudia Colciago, Investment Manager
Dr. Colciago started her career in digital health investments in 2017, when she joined MTIP, a Swiss-based investment team focused on healthtech startups. Her passion for digital health goes back to 2007 when, during her university studies, she worked along the academic team pioneering the application of advanced mathematical techniques to medical problems.
She has a Ph.D. in Applied Mathematics from the École Polytechnique fédérale de Lausanne (EPFL) in Switzerland. Her thesis was focused on fluid-structure interaction simulations of cardiovascular problems and her work has been published in major scientific journals.
During her post-doc studies, she led a proof of concept project of a digital health startup. She managed and contributed to the development of risk assessment software for vascular surgeons. In 2017, she obtained a certificate of advanced studies in "Management of medtech, biotech and pharma ventures" from EPFL.
During her years at MTIP, before joining Takeda, she led a $20+m financing round in Oviva and led/supported the first and/or follow-on investment in other portfolio companies such as Coramaze, Blueprint Genetics, Tyto Care, Lumeon, and Cynerio. She served as a board member in Coramaze. She has been invited as a panelist and jury member at international healthtech startups conferences.
Outside work, she spends time reading books, playing, and singing with her daughter and husband. She trains her problem-solving skills in the bouldering gym and she is passionate about mountaineering.
Rebecca Redfield, Investment Analyst
Rebecca graduated from Boston College's Carroll School of Management with a Bachelor's of Science in Finance and Business Analytics. During her time at Boston College, she was the Chair of a funding body responsible for allocating over $1M to student organizations and a member of the Undergraduate Government's Financial Affairs committee.
She began her career at Foundation Medicine where she spent two summers working on Cloud Cost Optimization and Cloud Governance. Rebecca is AWS Cloud Practitioner Certified. During her time at Foundation, Rebecca discovered the power of HealthTech and the benefit it offers patients. She is excited to learn more about the industry and play a role in empowering entrepreneurs to challenge the status quo of healthcare.
At Takeda, Rebecca has worked with the Cloud Business Office and Enterprise Architecture. She has been developing a technology acquisition governance process and also spearheaded the development of an Open-Source Software policy.
Rebecca currently resides in Cambridge, Massachusetts. Outside of work, Rebecca enjoys dancing, yoga, and spending time outside. She loves to hike and go to the beach.
Karl Hick is the Chief Digital & Information Officer at Takeda Pharmaceuticals. His nearly 20 years of experience in technology ranges from the transformation of global IT organizations to mergers, acquisitions, and divestitures, to cutting-edge digital health. Impacting patients’ lives has become a meaningful value-driver in Karl’s 12+ years in the pharmaceutical industry.
Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company, where Karl has led the efforts to create a diversified technology investment portfolio, including digital and AI. He has accelerated the strategic digital agenda through a Digital Advisory Board (DAB), demonstrating the value of cross-functional collaboration for a faster and more significant impact. Karl also serves as the Chairman of the Board of Managers for Takeda Digital Ventures (TDV). TDV is a venture fund focused on investing in digital health companies to improve patient outcomes.
With the $62B acquisition of Shire in January 2019, Karl is guiding the organization through the integration while driving digital innovation. He was the Chief Information Officer (CIO) at Shire before moving to Takeda in November 2017. Before joining Shire in 2013, Karl was the CIO of Novartis Vaccines and Diagnostics. Throughout his career, Karl actively engages in contributing to the technology community through his participation in various CIO Executive forums and his championing of technology development programs to increase diversity and inclusion.
Born in Greece, Karl went to university in the U.S. and China. He received his bachelor’s degree in Mechanical Engineering from Georgia Institute of Technology in Atlanta, Georgia, and completed a Technology Executive Leadership program at IMD in Lausanne, Switzerland.
Rajeev Venkayya is President of the Global Vaccine Business Unit at Takeda Pharmaceutical Company Ltd, where he leads a vertically-integrated business developing vaccines for dengue, norovirus and Zika. He serves as an independent member of the board of the Coalition for Epidemic Preparedness Innovations (CEPI), which is funding and coordinating several vaccine development programs for SARS-CoV-2 (the virus that causes COVID-19). He is also on the board of the International AIDS Vaccine Initiative (IAVI) and is a life member of the Council on Foreign Relations.
Dr. Venkayya is currently co-leading Takeda’s response to the COVID-19 outbreak, given his previous experience at the White House as Special Assistant to the President for Biodefense. In this role, he was the principal author of the National Strategy for Pandemic Influenza (2005), and his office led the development and execution of the companion Implementation Plan (2006). His team conceived the strategy of early, coordinated implementation of non-pharmaceutical interventions to slow the spread of a pandemic virus, now known as the “flattening the curve,” that was described in the US Government’s guidelines on community mitigation of pandemic influenza (2007). These guidelines were updated in 2017 to reflect the lessons of the 2009-H1N1 outbreak, and the concepts therein are being implemented or considered by governments around the world to slow the transmission of SARS-CoV-2.
Prior to joining Takeda, Dr. Venkayya served as Director of Vaccine Delivery at the Bill & Melinda Gates Foundation’s Global Health Program, where he was responsible for the foundations top two priorities of polio eradication and the introduction of new vaccines into developing countries through Gavi, the Vaccine Alliance. He also served on the board of Gavi.
Dr. Venkayya trained in Pulmonary & Critical Care Medicine at the University of California, San Francisco, where he also served on the faculty. He was a resident and Chief Medical Resident in internal medicine at the University of Michigan. He received his B.S./M.D. from the Northeast Ohio Universities College of Medicine, where he was inducted into the Alpha Omega Alpha honorary medical society.
Dr. Venkayya lives in Boston with his wife Viktoria and their two sons.
Meredith is a Partner at Mass General Brigham Ventures where she focuses on early stage investments and company creation. She serves on the board of Amolyt Pharma, ClarisBio, Mediar (where she is also interim CEO), Nocion, Scorpion and ZielBio. She has experience as an investor, founder and operator from her time at Bracebridge Capital, PureTech Health and Gingko Bioworks. In her early career, she was a research scientist first at Anadys (acquired by Roche) and then Idenix (acquired by Merck). Meredith received her undergraduate degree from Mount Holyoke College, her MBA from the MIT Sloan School of Management and her PhD from Harvard University.
Donald Jones, Operating Partner
Donald Jones is a globally recognized leader in digital medicine, digital therapies, technology enabled health services and virtual clinic business models. He is a sought out as a speaker, retained advisor and board member. He works across a spectrum of healthcare, pharmaceutical, medical device, wearable, smart apparel, material science and healthcare AI companies. He is an Operating Partner with Takeda Digital Ventures. As Chair of the Cardiff Ocean Group, he is an independent director on the boards of venture capital and private equity backed companies with investors including Searchlight Capital, L'Catterton Partners, Flex, Samsung, Omron, GE and Takeda. His Fortune 1000 Advisory Boards have included Flex, TEVA, JSR, Sanofi, Otsuka, Takeda, Astra Zeneca, Cepheid and MAS Holdings. Don has advised the Boards and executive suites of many of the largest pharmaceutical companies. He has the Verily/Sanofi joint venture, Onduo and advises Huami/PAI, the world’s largest wearables company. He is a Senior Advisor with both McKinsey & Company and the GLG Institute. Jones serves as Chief Digital Officer (Emeritus) of the Scripps Research Translational Institute (SRTI), an Institute within Scripps Research, collaborating with the renowned Eric Topol, MD. He co-founded Scripps Digital Medicine, the world’s first digital health clinical trial center and the non-profit West Health Institute, raising over $130 million.
For 11 years, Don led Qualcomm Wireless Health Global Strategy and Business Development and founded its healthcare subsidiary. In 2005 he founded the Wireless Life Sciences Alliance, merging with HIMSS in 2016 and is now Chairman Emeritus. Earlier in his career, Don was COO of MedTrans, which grew from $4.5 million into the largest emergency services provider in the US (now American Medical Response), with almost 30,000 paramedics. He was Founder and Chairman of EMME, the largest consumer membership healthcare provider (and largest private practice) in Mexico, with over 450 physicians. As advisor to the CEO and Board of AMR, he helped build the largest medical group in the US, under the EmCare brand, with over 25,000 physicians. In 2014, EvoNexus recognized Donald Jones as Digital Health Innovator of the Year. Don conceived the $10 million Qualcomm Tricorder XPRIZE, a global competition for a consumer device which successfully makes medical diagnoses. The XPRIZE was awarded in Hollywood in April 2017.
Dr. Pat Basu, Advisor
Former Stanford physician and White House Advisor, Pat A. Basu, MD, MBA, is President and Chief Executive Officer of Cancer Treatment Centers of America Global, Inc., which includes the Cancer Treatment Centers of America® (CTCA) Comprehensive Cancer Care Network of hospitals and outpatient care centers as well as new business ventures designed to expand access to the network’s high-quality oncology care. He also serves as a member of the CTCA National Board of Directors.
Dr. Basu has held numerous senior executive positions in the health care and private equity sectors. He co-founded Doctor on Demand, a pioneering telehealth service and the largest provider of telehealth video visits in the US. He also led several businesses for Optum/UnitedHealth, the largest health care firm in the United States, where he served as Senior Vice President and member of the Executive Leadership Team.
Dr. Basu also served as President, Chief Operating Officer and Chief Medical Officer at vRad, a transformative telehealth provider that delivers timely and quality radiology services to millions of patients, and he was a co-founder of Extend MD, a web portal designed to enhance outpatient care, and of STARS Luncheon, a nonprofit that supports the career success of disadvantaged children. He has been a member of the advisory boards of Walgreens, General Electric, CareCredit, the McKinsey & Co. management consultant firm and the American Medical Association and has consulted for several Fortune 500 firms, venture capital firms and large hospital systems. Most recently, he was a partner at Chicago Pacific Founders Private Equity & Pritzker Group Venture Capital.
Outside the corporate realm, Dr. Basu has assumed many community and public service leadership roles. A board-certified radiologist with expertise in treating cancer patients, Dr. Basu continues to provide care to veterans at the Veterans Administration Hospital System. He has served on The Council on Foreign Relations, the United States-Japan Foundation, the Illinois State Board of Health, the University of Illinois’ Institute of Government & Public Affairs and as a Regional Commissioner of the White House Fellows. Today, he sits on the Board of Directors for the University of Illinois and the Stanford University Medical Alumni Association.
Dr. Basu earned his Bachelor of Science degree in mechanical engineering from the University of Illinois. He later received his medical degree from the University of Chicago, while simultaneously earning a master’s in business administration (MBA) from the university’s Booth School of Business. He then went on to complete the Stanford Business School’s Faculty Leadership Program, teaching Stanford medical and MBA students, among other responsibilities, in his role as Founding Faculty Director of Health Policy and Finance.
Dr. Basu took a leave of absence from Stanford University to serve as a White House Fellow and Senior Advisor, serving at the highest levels of federal government while helping to execute portions of then-President Obama’s economic and health agenda.
Dr. Basu is a recipient of the American Medical Association’s National Excellence Award for Leadership, the Crain’s Chicago Business 40 Under 40 Award, Stanford Medicine’s Physician of the Year Award, University of Illinois Distinguished Alumni Award and the University of Chicago Booth School of Business’ Distinguished Alumni Award. He has delivered keynote addresses at over 150 corporations, universities, governments and professional societies and has provided expert commentary and opinion numerous times on CBS, NBC, WGN, NPR and other national networks.
Dave Icke, Advisor
Dave Icke is the Vice President of Humana Digital Health and Analytics (DH&A) Products. He is responsible for co-creating the company’s virtual care strategy with its various lines of business and working alongside the industry’s digital health ecosystem to forge partnerships with organizations on the leading-edge of technology and innovation. This includes developing and iterating human-centered products on the DH&A platform to enable differentiated health care experiences in support of the organization’s integrated care delivery model.
For more than 20 years, Dave’s career has been focused on growing and scaling businesses that solve industry challenges with breakthrough technology. Prior to joining Humana, he served as the Vice President and General Manager of Digital Health at medical technology leader Becton Dickinson. In this role, Dave started a business unit focused on developing consumer-centric software solutions for chronic disease patients outside the hospital. In addition, Dave served as the founding Chief Executive Officer of MC10, a leading supplier of wearable, biometric sensing solutions for sports, medical technology and digital health.
Dave has also advised a range of private and public companies across the digital health space including Hatch@Takeda, Profusa, Flex, Qualcomm Life and Twine Health.
He earned a Bachelor’s of Science degree in chemical engineering from Stanford University and a master’s degree in business administration from the Harvard Business School.
Dave enjoys skiing, hiking and international travel.
Robert Watson, Advisor
Rob is a Managing Director at Altaris Capital Partners, a leading healthcare-focused private equity firm based in New York, where he leads the firm’s investment in Pharma and life sciences sectors. He has broad experience in investing across the healthcare and technology industries, in companies based in Europe, the US and in Asia. Prior to Altaris, he worked at HgCapital in London, Ares Life Sciences in Geneva, and Soffinova partners in Paris.
Before investing Rob was a neuroscientist and has published research into neurodegenerative diseases. He has an BioChem in BioChemistry and a DPhil in Neurology from the University of Oxford.
Janine Kopp, Entrepreneur in Residence
Janine Kopp started her career in 2016 as a Product Manager for a cancer therapeutic at Takeda for the Swiss Market, and later for the European and Canadian markets. She developed deep insights into the Oncology market and led the path towards indication expansions and growth in the region together with a cross-functional team.
Since 2019, she has been involved in the early phases of Takeda Digital Ventures and the strategic development of the fund. As a Venture Associate, she supported the investments in Seqster and Amwell, as well as the exit of Gaido Health.
To gain operational experience as an entrepreneur, Janine took a sabbatical in 2020 to found a virtual care Women’s Health Company. She joined the Takeda Digital Ventures team again in May 2021 as an Entrepreneur in Residence.
In her free time, Janine enjoys going on walks with her Corgi Gnocchi and her husband, exploring the beautiful landscapes of Austria, and practicing mindfulness and Yoga.
Janine has a Master of Science in Medicinal and Industrial Pharmaceutical Sciences (MIPS) and a Bachelor of Science in Pharmaceutical Sciences, both from ETH Zurich. At ETH, she conducted research in the Biomacromolecules group of Prof. Neri, where her research on the role of T-cells in cancer got published in the journal Cancer Research.
Anja Barmoha, Business Analyst
Anja Barmoha, Business Analyst joined Takeda headquarters in Zurich in November 2016. Anja has built her international career in administration. She has lived in Sweden, Israel and USA. Prior to Takeda Anja has worked 6 years at Bombardier Transportation in Sweden in the field of administration supporting the production and engineering departments. Anja also has many years of experience from New York in the field of advertising and marketing.
Born in Sweden, Anja went to Pace University in New York City and received her Bachelor’s degree of Business Administration in International Marketing. Anja is trilingual and speaks English, Swedish and German. Outside of work Anja enjoys running, bicycling, skiing and travelling. Anja lives in Zurich with her husband and two boys.
Héctor Röthlisberger is a lawyer by profession and joined Takeda in December 2012, he is based in Zurich, Switzerland. Prior to Takeda, Héctor advised Actelion Pharmaceuticals (a Johnson & Johnson company) in Basel, Switzerland, where he served as a legal advisor in R&D, litigations and regulatory matters. In 2018, Héctor joined Takeda Digital Ventures and assisted in the establishment of the corporate venture capital fund. His responsibilities include strategic and legal advising of Takeda Digital Ventures on all corporate matters, venture capital financing transactions, governance, strategic partnerships, and commercial agreements. Héctor leads a team of lawyers at Takeda who are devoted to the commercialization of the Takeda product pipeline across Europe, Canada and Emerging Markets, and who are offering legal services to maximize Takeda’s product franchises, with expertise in regulatory, commercial, public and global health, and with special focus on digital health and emerging technologies. Héctor holds a law degree from the University of Basel, with extra faculty credits in political economics and applied social studies, and is fluent in English, German, Spanish and French.